Sean D. Sullivan
The fertility of our minds to invent health care technology must now be matched by a commitment to assess and identify its appropriate use.
EducationPhD University of California (Berkeley), 1992 (Health Economics)
MS University of Texas (Austin), 1986 (Pharmacy)
BS Oregon State University, 1983 (Pharmacy)
Contact Infoemail: email@example.com
office: H-375, Health Sciences Building
1959 NE Pacific Street
Seattle, WA 98195-7630
campus box: 357630
Sean D. Sullivan is Professor and Dean of the University of Washington School of Pharmacy. In addition to his joint appointment as Professor of Health Services, He also holds adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at Kaiser Permanente Washington Health Research Institute.
Dr. Sullivan has authored more than 400 journal articles, book chapters, task force reports and organizational and governmental publications. In many of these, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include technology assessment, medical decision-making and economic evaluation of medical technology. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) executive committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision-making.
Dr. Sullivan served as a member of the Medicare Evidence Development and Coverage Advisory Committee, a member of the Regence Blue Shield and Premera Blue Cross P/T Committee and chair, Premera Blue Cross Value Assessment Committee. He is also on the editorial boards of Value in Health, PharmacoEconomics, and Journal of Medical Economics. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy and the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award.
Kim DD, Arterburn DE, Sullivan SD, Basu A. Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Med Care. 2018 Jul;56(7):583-588. doi: 10.1097/MLR.0000000000000924. PMID: 29762271
Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13345. [Epub ahead of print] PMID: 29938887 PMCID: PMC6099352
Olchanski N, Hansen RN, Pope E, D'Cruz B, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infect Dis. 2018 Feb 7;5(3):ofy031. doi: 10.1093/ofid/ofy031. eCollection 2018 Mar. Review. PMID: 29516023 PMCID: PMC5833316
Slejko JF, Basu A, Sullivan SD. Returns to scientific publications for pharmaceutical products in the United States. Health Econ. 2017 Jul 10. doi: 10.1002/hec.3546. [Epub ahead of print] PMID: 28695605
- Cancer drug prices climb after market launch (Health Affairs, 05/10/2016)
- Sean D. Sullivan Named Dean of UW School of Pharmacy
- Steroid Injections Offer Little Relief for Spinal Stenosis
- Why Is It So Hard To Find The Price Of A Medical Procedure?
- Heroin Overdose Antidote Kits Cost Effective